美股A股
StockGist
Back
8-K2026-03-19· x-ai/grok-4.1-fast

ARMP · Armata Pharmaceuticals, Inc.

0001104659-26-031715

SEC filing

Summary

Armata Pharmaceuticals, Inc. announced a delay in its fourth quarter and full-year 2025 financial results announcement, anticipating filing its Form 10-K on or before March 31, 2026, and provided a corporate update including FDA QIDP designation for AP-SA02, Phase 3 trial plans, cGMP facility commissioning, and positive Phase 2a study results.

Key takeaways